Shamburg News · 8-K filed Nov 16, 2026, 5:04 PM EST

ENDRA Life Sciences Reports Third Quarter 2026 Results and Pending Noble Africa Merger Update

NDRA · ENDRA Life Sciences Inc.

  • Earnings
  • Other event
  • Materiality: high

ENDRA Life Sciences reported a net loss of $1,528,528 for the quarter ended September 30, 2026, compared with a net loss of $1,595,959 in the prior-year quarter, with a net loss per share of $(1.02). Operating expenses were $1,715,163, and the company reported $1.5 million in unrestricted cash, $3.4 million in restricted cash, and digital assets as of September 30, 2026. The press release, furnished as Exhibit 99.1, also updated on the proposed merger with Noble Africa LLC, a subsidiary of ASP Isotopes Inc., which is subject to stockholder approval and other closing conditions.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001213900-26-120816.

Written from the filing by Shamburg Markets. Figures are as reported by the company.